Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lactoferrin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All ivermectin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19ivm.org COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Azvudine Meta Metformin Meta
Bromhexine Meta
Budesonide Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Famotidine Meta Nitazoxanide Meta
Favipiravir Meta Paxlovid Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Recovery 68% primary Improvement Relative Risk Recovery (b) 27% Recovery (c) 75% Ivermectin  Faisal et al.  EARLY TREATMENT  RCT Is early treatment with ivermectin beneficial for COVID-19? RCT 100 patients in Pakistan (April - May 2020) Improved recovery with ivermectin (p=0.005) c19ivm.org Faisal et al., The Professional Medica.., May 2021 Favors ivermectin Favors control

Potential use of azithromycin alone and in combination with ivermectin in fighting against the symptoms of COVID-19

Faisal et al., The Professional Medical Journal, doi:10.29309/TPMJ/2021.28.05.5867
May 2021  
  Twitter
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
RCT 100 outpatients in Pakistan, 50 treated with ivermectin, showing faster recovery with ivermectin. All patients received AZ, zinc, vitamin C, vitamin D, and paracetemol. Details of randomization were not provided. No mortality or hospitalization was reported.
This is the 24th of 46 COVID-19 RCTs for ivermectin, which collectively show efficacy with p=0.00000014.
This is the 53rd of 99 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 2 sextillion).
risk of no recovery, 68.4% lower, RR 0.32, p = 0.005, treatment 6 of 50 (12.0%), control 19 of 50 (38.0%), NNT 3.8, 6-8 days, mid-recovery, primary outcome.
risk of no recovery, 27.3% lower, RR 0.73, p = 0.11, treatment 24 of 50 (48.0%), control 33 of 50 (66.0%), NNT 5.6, 3-5 days.
risk of no recovery, 75.0% lower, RR 0.25, p = 0.09, treatment 2 of 50 (4.0%), control 8 of 50 (16.0%), NNT 8.3, 9-10 days.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Faisal et al., 10 May 2021, Randomized Controlled Trial, Pakistan, peer-reviewed, 3 authors, study period 5 April, 2020 - 30 May, 2020, dosage 12mg days 1-5.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Potential use of azithromycin alone and in combination with ivermectin in fighting against the symptoms of COVID-19.
Dr Rizwan Faisal, Syed Furqan Ali Shah, Mazhar Hussain
The Professional Medical Journal, doi:10.29309/tpmj/2021.28.05.5867
Material & Methods: Total patients included in the study were 100. Patients were divided into two groups by systematic random sampling: Group A: who received AZM (500mg once a day for 5 days), Group B: who received Ivermectin (12mg once a day for 5 days) and AZM (500mg once a day for 5 days). All the participants were informed to revisit hospital as soon as symptoms (at least two of the mentioned symptoms) like fever, fatigue, sore throat, cough, body aches/myalgia, anosmia/hyposmia, ageusia/hypogeusia and diarrhea disappears at least for 3 days (the actual day on which symptom(s) disappeared was noted). They were also advised to revisit hospital if they feel any inconvenience with the treatment or they notice worsening of the symptoms. The efficacy of the two regimens was based on the duration of disappearance of symptoms. RT-PCR was repeated after 15 days of the diagnosis and on day 21 who came positive on day 15. Results: In group A, the symptoms of 34% patients started to disappear during 3-5 days (mean±SD, 4.86 ± 0.42 days) following therapy, it disappeared during 6-8 days (7.18 ± 0.37) in 28% patients, 22% were symptom free during 9-10 days (10.12 ± 0.12), and 16% took ˃10 days to become symptom free (12 ± 0.26). Similarly, 52% of group B patient were relieved during 3-5 days (4.01 ± 0.32) of therapy, 36% were symptom free during 6-8 days (6.32 ± 0.14), symptoms of 8% disappeared during 9-10days (9.06 ± 0.25), and 4% took ˃10 days (11 ± 0.0) to become symptom free. Conclusion: Combination of ivermectin and azithromycin was more effective in making patients symptom free than azithromycin alone.
References
Ang, Lee, Choi, Zhang, Lee, Herbal medicine and pattern identification for treating COVID-19: A rapid review of guidelines, Integr Med Res
Campbell, Benz, Ivermectin: a review of efficacy and safety, J Vet Pharmacol Ther
Canga, Prieto, Liébana, Martínez, Vega et al., The pharmacokinetics and interactions of ivermectin in humans--a mini-review, AAPS J
Crump, Omura, Ivermectin, 'wonderdrug' from Japan: The human use perspective, Proceed Japan Acad Series B
Crump, Ōmura, Ivermectin, 'wonder drug' from Japan: The human use perspective, Proc Jpn Acad Ser B Phys Biol Sci
Faisal, Rehman, Bahadur, Shinwari, Problem based learning in comparison with lecture based learning among medical students, Journal of Pakistan Medical Association
Faisal, Shinwari, Izzat, Academic performance of day scholars versus boarders in pharmacology examinations of a medical school in Pakistan, J Pak Med Assoc
Götz, Magar, Dornfeld, Giese, Pohlmann et al., Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import, Sci. Rep
Kircik, Rosso, Layton, Schauber, Over 25 years of clinical experience with ivermectin: An overview of safety for an increasing number of indications, J Drugs Dermatol
Laing, Devaney, Ivermectin-old drug, new tricks?, Trends Parasitol
Lu, Chen, Chang, Potential therapeutic agents against COVID-19: What we know so far, J Chin Med Assoc
Lu, Stratton, Tang, Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle, J Med Virol
Lundberg, Pinkham, Baer, Amaya, Narayanan et al., Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan Equine Encephalitis Virus replication, Antivir. Res
Sohrabi, Alsafi, Neill, World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19), Int J Surg
Tay, Fraser, Chan, Moreland, Rathore et al., Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin Antivir, Res
Voorhis, Huijsduijnen, Profile, William, Campbell et al., Nobel Laureates in Physiology or Medicine, Proc Natl Acad Sci
Wagstaff, Rawlinson, Hearps, Jans, An Alpha Screen(R)-based assay for high-throughput screening for specific inhibitors of nuclear import, J. Biomol. Screen
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of over 100,000 datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit